Moderna’s RSV vaccine gets Breakthrough Therapy status

Moderna Inc.
MRNA,
-2.01%
said Monday that the Food and Drug Administration granted the company’s experimental respiratory syncytial virus vaccine a Breakthrough Therapy Designation. Moderna said it plans to apply for approval in the first half of this year. The company’s stock has gained 18.7% over the past year, while the S&P 500
SPX,
+0.25%
is down 4.3%.